The US Food and Drug Administration has proposed an enforcement framework for certain federally registered facilities that compound animal drugs from bulk drug substances in accordance with current good manufacturing practice (CGMP) requirements.
Draft Guidance for Industry #256B addresses facilities registered with FDA under sections 503B(b) or 510(b) of the Federal Food, Drug, and Cosmetic Act. These facilities can include outsourcing operations for manufacturing or compounding human drugs, approved animal drugs, and other products within the same establishment.
The draft guidance would extend FDA’s enforcement-discretion policies to certain federally registered facilities that comply with applicable state laws but are not necessarily state-licensed pharmacies. Comments are due November 27, 2026.
FDA distinguishes CGMP from enforcement discretion
The draft supplements FDA’s existing Guidance for Industry #256, which describes the agency’s enforcement priorities for animal drugs compounded from bulk drug substances by or under the direct supervision of pharmacists in state-licensed pharmacies and federal facilities.
Under the new proposal, eligible federally registered establishments could compound certain animal drugs within an enforcement-discretion framework. However, FDA states that it generally would not exercise enforcement discretion for violations of CGMP requirements at these facilities.
That distinction matters when a single organization produces several product categories under different regulatory conditions. FDA explains that inconsistent quality standards within one registered facility could complicate inspections and create uncertainty about which facility-wide CGMP controls apply.
For quality-control laboratories, the issue extends beyond where products are physically compounded. Samples, reference materials, methods, instruments, records, and computerized systems can cross operational boundaries if managers do not clearly define them.
Shared operations require clear separation
FDA recommends complete segregation of CGMP and non-CGMP operations when a federally registered outsourcing facility is also a state-licensed pharmacy and chooses to operate under the applicable compounding policies.
The draft also recommends clear labeling for products not produced under CGMP. For example, a facility could state on the label that a drug was not compounded under CGMP or distribute it under a name different from the one associated with the facility’s federal registration.
Laboratory managers at affected facilities should map the flow of samples and data through their operations. The review should identify shared analysts, instruments, storage areas, LIMS workflows, test methods, and document templates. Managers can then determine whether procedural controls provide adequate separation or whether dedicated resources are necessary.
Guidance on GMP and non-GMP work in shared environments emphasizes labeling and segregation to reduce the possibility of cross-contamination or misidentification. The same principles apply to laboratory samples and records, even when production occurs elsewhere in the facility.
Documentation must preserve each product’s status
Laboratories may need separate sample identifiers, specifications, worksheets, approval pathways, and release controls for CGMP and non-CGMP materials. Electronic systems should restrict unauthorized changes while preserving the status and history of each record.
Strong data-integrity practices in pharmaceutical quality-control laboratories become especially important when employees and instruments support multiple regulatory workflows. Training records should also show that analysts understand which procedures apply to each activity.
The document remains draft guidance and contains nonbinding recommendations. Affected laboratory and quality leaders should review it before changing procedures and consider commenting on practical issues involving shared equipment, staffing, data systems, and facility layouts.
If FDA finalizes the policy, the central management challenge will be maintaining a demonstrable boundary between operations governed by CGMP and those conducted under a different framework. That boundary must remain visible not only on the production floor, but also throughout laboratory testing, review, documentation, and product disposition.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
